Diseño de un oscilador controlado por tensión (VCO) en tecnología SiGe 0.35 µm para el estándar DVB-H

Presentación del Proyecto Fin de Carrera titulado "DISEÑO DE UN OSCILADOR CONTROLADO POR TENSIÓN (VCO) EN TECNOLOGÍA SiGe 0.35 µm PARA EL ESTÁNDAR DVB-H"

Diseño de un mezclador para un receptor de UWB en tecnología SiGe 0.35 μM de AMS

Presentación del Proyecto Fin de Carrera titulado "DISEÑO DE UN MEZCLADOR PARA UN RECEPTOR DE UWB EN TECNOLOGÍA SiGe 0.35 μM DE AMS"

Diseño de un convertidor de corriente en tecnología CMOS 0.35

Proyecto y presentación del Proyecto Fin de Carrera titulado "Diseño de un convertidor de corriente en tecnología CMOS 0.35"

Diseño de un modulador GFSK integrado en tecnología SiGe 0.35μm de AMS

Presentación del Proyecto Fin de Carrera titulado "DISEÑO DE UN MODULADOR GFSK INTEGRADO EN TECNOLOGÍA SiGe 0.35μm de AMS"

Diseño de un filtro integrado sintonizable en tecnología CMOS 0.35μm

Especialidad: Sistemas Electrónicos

Outcome after radical cystectomy with limited or extended pelvic lymph node dissection

PURPOSE: We compared recurrence patterns and survival of patients with urothelial bladder cancer undergoing radical cystectomy who either had limited or extended pelvic lymph node dissection at 2 institutions between 1987 and 2000. MATERIALS AND METHODS: Two consecutive series of patients treated with radical cystectomy and limited pelvic lymph node dissection (336; Cleveland Clinic) and extended pelvic lymph node dissection (322; University of Bern) were analyzed. All cases were staged N0M0 prior to radical cystectomy, and none were treated with neoadjuvant radiotherapy or chemotherapy. Patients with PTis/pT1 and pT4 disease were excluded from analysis. Pathological characteristics based on the 1997 TNM system and recurrence patterns were determined. RESULTS: The overall lymph node positive rate was 13% for patients with limited and 26% for those who had extended pelvic lymph node dissection. The 5-year recurrence-free survival of patients with lymph node positive disease was 7% for limited and 35% for extended pelvic lymph node dissection. The 5-year recurrence-free survival for pT2pN0 cases was 67% for limited and 77% for extended pelvic lymph node dissection, and the respective percentages for pT3pN0 cases were 23% and 57% (p <0.0001). The 5-year recurrence-free survival for pT2pN0-2 cases was 63% for limited and 71% for extended pelvic lymph node dissection, and for pT3pN0-2 cases the respective figures were 19% and 49% (p <0.0001). Incidence of local and systemic failure correlated closely with pathological stage for both series. CONCLUSIONS: Our data suggest that limited pelvic lymph node dissection is associated with suboptimal staging, poorer outcome for patients with node positive and node negative disease, and a higher rate of local progression. Extended pelvic lymph node dissection allows for more accurate staging and improved survival of patients with nonorgan confined and lymph node positive disease.

Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years

BACKGROUND/AIMS: Alveolar echinococcosis (AE) is a serious liver disease. The aim of this study was to explore the long-term prognosis of AE patients, the burden of this disease in Switzerland and the cost-effectiveness of treatment. METHODS: Relative survival analysis was undertaken using a national database with 329 patient records. 155 representative cases had sufficient details regarding treatment costs and patient outcome to estimate the financial implications and treatment costs of AE. RESULTS: For an average 54-year-old patient diagnosed with AE in 1970 the life expectancy was estimated to be reduced by 18.2 and 21.3 years for men and women, respectively. By 2005 this was reduced to approximately 3.5 and 2.6 years, respectively. Patients undergoing radical surgery had a better outcome, whereas the older patients had a poorer prognosis than the younger patients. Costs amount to approximately Euro108,762 per patient. Assuming the improved life expectancy of AE patients is due to modern treatment the cost per disability-adjusted life years (DALY) saved is approximately Euro6,032. CONCLUSIONS: Current treatments have substantially improved the prognosis of AE patients compared to the 1970s. The cost per DALY saved is low compared to the average national annual income. Hence, AE treatment is highly cost-effective in Switzerland.

Report on the Ermont Mine Sec. 35, T. 6 S., R. 11 W., Beaverhead County, Montana

An examination of the Ermont Mine was requested by the owners, Messrs. J. R. Bowles and R. B. Caswell, to determine the amount and grade of ore developed, the advisability of constructing a mill at the present time, and to recommend future development work.